Relay Therapeutics, Inc.
RLAY
Updated: 23/09/2026, 14:08:34
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
No summaries found.
- Share price
- $19.35
- Market cap
- $4.24B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Sanjiv K. Patel
- Employees
- 202
- IPO date
- 16/07/2020
- Beta
- 1.696
- Last dividend
- $0.00
- Day range
- $18.21 – $19.47
- 52-week range
- $4.32 – $21.27
- 1-day performance
- 6.38%
- 1-year performance
- 347.92%
- Current drawdown (1Y)
- -9.03%
- CIK
- 0001812364
- CUSIP
- 75943R102
- ISIN
- US75943R1023
- Created
- 07/12/2025, 14:00:24
- Last update
- 23/09/2026, 14:08:34
Track Relay Therapeutics, Inc. with an AI analyst
See which prediction-market events move RLAY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
GlobeNewsWire • STOCK • 27/05/2026, 18:05:00
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewsWire • STOCK • 20/05/2026, 22:21:00
Why Relay Therapeutics Stock Popped on Wednesday
The Motley Fool • STOCK • 20/05/2026, 21:01:49
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
Seeking Alpha • STOCK • 20/05/2026, 06:50:17
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
Seeking Alpha • STOCK • 20/05/2026, 01:10:53
Relay's treatment shown to shrink vascular malformations in mid-stage trial
Reuters • STOCK • 19/05/2026, 08:02:38
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript
Seeking Alpha • STOCK • 27/04/2026, 18:21:31
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
Zacks Investment Research • STOCK • 06/04/2026, 12:15:29
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
GlobeNewsWire • STOCK • 02/04/2026, 18:05:00
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 11/03/2026, 13:42:22
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Zacks Investment Research • STOCK • 11/03/2026, 11:06:09
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Seeking Alpha • STOCK • 06/03/2026, 16:45:57